Shares of I-Mab (IMAB) jumped over 10% on Friday morning after the Chinese biotech company announced a collaboration deal with AbbVie Inc. (ABBV) to develop and sell I-Mab's lemzoparlimab for the treatment of multiple cancers. The deal could be worth more than $2 billion.
IMAB is currently trading at $39.67, up $3.90 or 10.90%, on the Nasdaq.
Under terms of the agreement, AbbVie will pay I-Mab $200 million, including a $180 million upfront payment and $20 million in a milestone payment based on Phase 1 trial results. In addition, I-Mab will be eligible to receive up to $1.74 billion in milestone payments, including up to $840 million for clinical development and regulatory approval milestones and the rest on commercialization milestones. AbbVie will also pay royalties from low-to-mid teen percentages on lemzoparlimab international sales.
Separately, I-Mab also announced that a consortium led by Hillhouse Capital has agreed to invest $418 million through a private placement. The deal includes an offering of 29.1 million shares at $33 for each of I-Mab's American depositary shares, according to a statement. The placement will also see the issue of warrants worth an additional $104.5 million if fully exercised.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.